Previous 10 | Next 10 |
Orchard Therapeutics plc (ORTX) is expected to report $-1.3 for Q3 2023
NEW YORK, NY / ACCESSWIRE / October 28, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Mirati Therapeutics, Inc. (NASD...
BOSTON and LONDON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced a range of interim clinical outcomes, in addition to the previously reported neurological and skeletal results, from the company’s ongoing proof-of-concep...
Eight presentations highlight the differentiated profile and broad applicability of the company’s HSC gene therapy platform Data from proof-of-concept study of OTL-203 in MPS-IH demonstrate favorable outcomes for clinical manifestations of the disease not well addressed by the cu...
NEW YORK, NY / ACCESSWIRE / October 9, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: SP® Plus Corporation (NASDA...
2023-10-05 12:59:42 ET More on Grupo Aeroportuario del Centro Norte, Grupo Aeroportuario del Pacifico, etc. For further details see: BTWN, OMAB and PAC among mid-day movers
2023-10-05 11:37:13 ET Shares of the commercial-stage gene therapy company Orchard Therapeutics (NASDAQ: ORTX) were up by a noteworthy 98% on sky-high volume as of 10:13 a.m. ET Thursday morning. The biotech's stock is rocketing higher on the news that the Japanese biopharma Kyowa...
2023-10-05 10:38:59 ET Shares of Orchard Therapeutics (NASDAQ: ORTX) almost doubled this morning after Kyowa Kirin Co Ltd (TYO: 4151) announced plans of buying the gene therapy company. Details of Orchard-Kyowa definitive agreement The Japanese specialty pharmaceutical firm is w...
2023-10-05 10:00:20 ET More on Health Care Select Sector SPDR BofA Securities: Which small cap non-earner stocks to avoid Citi turns cautious on pharmaceuticals and biotech For further details see: Orchard Therapeutics, Longeveron among healthcare movers
Shares of Orchard Therapeutics PLC (NASDAQ: ORTX) traded at a new 52-week high today and are currently trading at $15.94. So far today, approximately 5.04M shares have been exchanged, as compared to an average 30-day volume of 101.26k shares. Orchard Therapeutics PLC, a biopharmaceutical comp...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....